Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 205.00 +1.68 (+0.83%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biogen Idec < Previous 1 2 ... 5 6 7 8 9 10 11 12 13 ... 46 47 Next > Thoughts For Thursday: Staying On Top - Barely November 09, 2023 The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago. Via Talk Markets Biogen (BIIB) Q3 2023 Earnings Call Transcript November 08, 2023 BIIB earnings call for the period ending September 30, 2023. Via The Motley Fool Topics Earnings Exposures Financial Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides November 08, 2023 Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the con Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session November 08, 2023 Via Benzinga Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics November 08, 2023 Biogen Inc. reported $2.53 billion in revenue for the quarter ended September 2023. Via Talk Markets Looking Into Biogen's Recent Short Interest November 06, 2023 Via Benzinga Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years November 01, 2023 Via Benzinga Assessing Biogen's Performance Against Competitors In Biotechnology Industry October 30, 2023 Via Benzinga US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings November 08, 2023 Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into... Via Benzinga Topics Economy Exposures Interest Rates Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount November 08, 2023 The company shares in the profits and sales related to Alzheimer's treatment, Leqembi. Via Investor's Business Daily 3 Biotech Moonshots to Bet on the Future of Health November 06, 2023 Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property $1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today October 18, 2023 Via Benzinga Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry October 16, 2023 Via Benzinga BIIB Stock Price Analysis: To Bet Or To Fold The Cards October 14, 2023 Massachusetts-based Biogen (BIIB) is a global biotechnology leader, researching and developing therapies for debilitating diseases impacting the central nervous system. Via Talk Markets Analyst Ratings for Biogen October 11, 2023 Via Benzinga Biogen Appoints Monish Patolawala to its Board of Directors November 06, 2023 Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation From Biogen Inc. Via GlobeNewswire Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment October 26, 2023 Both companies are working on under-the-skin injections for Alzheimer's treatment. Via Investor's Business Daily Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On October 25, 2023 From Biogen Inc. Via GlobeNewswire Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease October 25, 2023 Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, Via Benzinga New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease October 25, 2023 From Biogen Inc. Via GlobeNewswire An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week October 24, 2023 Another RSI Buy In a post last month, we wrote about the power of RSI (Relative Strength Index) as a technical indicator (Relative Strength Index) in relation to Stitch Fix, Inc. (NASDAQ: SFIX) Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session October 23, 2023 Via Benzinga Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting October 19, 2023 From Biogen Inc. Via GlobeNewswire 3 Struggling Stocks Investors Shouldn't Buy on the Dip October 18, 2023 These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better. Via The Motley Fool Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage October 13, 2023 The U.S. Via Benzinga 7 Low-Volatility Stocks to Buy if You’re a Concerned Investor October 11, 2023 With market and economic conditions worrying many investors, it may be time to consider the virtues of low-volatility stocks. Via InvestorPlace Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready October 11, 2023 Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... Via Benzinga LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly October 10, 2023 Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ: Via Benzinga Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio October 07, 2023 Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. Meanwhile, Biogen... Via Talk Markets Topics Initial Public Offering Exposures Securities Market Biotech Sector: On The Verge Of Triumph Or Turmoil? October 06, 2023 In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. Via Talk Markets < Previous 1 2 ... 5 6 7 8 9 10 11 12 13 ... 46 47 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.